Blood bacteria assay
This article was originally published in The Gray Sheet
Executive Summary
Use of a procalcitonin-guided assay can substantially reduce unnecessary antibiotic use in patients with lower respiratory tract infections, according to a study in the Feb. 21 issue of The Lancet. The 243-patient trial found that by testing for the presence of procalcitonin, which is elevated in bacterial infections, physicians were able to prevent antibiotic use in 39 out of 100 patients with viral infections, which do not respond to antibiotics...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.